RAINライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 1月 2024 @ 06:00):

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States...

Stats
本日の出来高	3.70M
平均出来高	238 293
時価総額	44.01M
EPS	$0 ( 2024-03-14 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.585
ATR14	$0.0380 (3.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-26	Tang Kevin C	Sell	3 850 513	Common Stock
2024-01-25	Bvf Partners L P/il	Sell	185 388	Common Stock, $0.001 par value
2024-01-25	Bvf Partners L P/il	Sell	341 547	Non-Voting Common Stock, $0.001 par value
2024-01-26	Bvf Partners L P/il	Sell	35 000	Stock Option (Right to Buy)
2024-01-26	Bvf Partners L P/il	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
-57.17
Last 98 transactions
Buy: 6 387 020 \| Sell: 11 238 556

ボリューム相関

長: 0.27 (neutral)

短: -0.45 (neutral)

Signal:(53.89) Neutral

Rain Therapeutics Inc. 相関

10 最も正の相関
ATRO	0.888
ORIC	0.886
PFMT	0.881
MDWD	0.878
VRNA	0.874
PRQR	0.874
IMVT	0.873
FTFT	0.869
IPHA	0.868
PMTS	0.865

10 最も負の相関
SGLB	-0.843
SFET	-0.839
OP	-0.835
AMGN	-0.832
PEV	-0.827
RTPY	-0.822
SMIT	-0.82
GHVI	-0.819
MEDS	-0.818
MTEX	-0.818

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Rain Therapeutics Inc. 相関 - 通貨/商品

-0.38
( neutral )

0.51
( weak )

0.00
( neutral )

0.05
( neutral )

0.40
( neutral )

0.44
( neutral )

Rain Therapeutics Inc. 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.71

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-2.71

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.942

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.980

Financial Reports:

No articles found.

Rain Therapeutics Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.